Vertex 809-110

Trial Status: 

A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation


Roll Over study with Combination Therapy Ivacaftor and Lumacaftor in Children 6-11 for Cystic Fibrosis homozygote genotype DeltaF508. 


Vertex Pharmaceuticals

Principal Investigator:

 Cori Daines, MD

Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Principal Investigator: 
Research Area: 
Clinical and Population Research